Specific Comments 1- Fig. S1B appears incorrect as At5g47280, which in the phylogeny is the closest homolog to At5g48650 (AtG3BP1), encodes an unrelated R protein. The phylogeny should also include HsG3BP1 to substantiate a claim of 'closest homolog to HsG3BP1' (p. 6). 2-As GFP itself localizes similarly, a GFP western to verify accumulation of full-length AtG3BP1-GFP fusion is required for Fig. 2B . 3-Considering the phenotypic characterization, the plants were grown at a relatively high temperature (23ºC) which may well mask cpr/autoimmune phenotypes as many R genes are less active at higher temperatures. Also, only 4 week-old plants are shown such that phenotypes may not be fully developed yet. The authors should grow the plants at lower temperatures, include pictures at later developmental stages, and stain tissues with trypan blue to detect any microscopic cell death or lesions. 4-For the resistance assays, the authors need to show 0 hpi in spray assays to rule out different inoculum input as the source for the differences at 3hpi. 5-AtG3BP1 was chosen as phosphorylation of Ser257 is slightly increased following FLG22 treatment, presumably by a MAP kinase. Is there any effect of mutation of Ser257 (Ser-Ala or Glu) on the proposed function(s) of AtG3BP1? 6-Atg3bp1-1 presumably expresses an mRNA at ~10% WT levels of an mRNA encoding the NTF2 domain while Atg3bp1-2 (typoed in Fig. 1E&G ) expresses appreciable levels of an almost fulllength AtG3BP1. Is this the case, as the qPCR with upstream exon primers would not reveal this? In addition, it would be far cleaner to generate Atg3bp1 knockouts by CRISPER-Cas, and comparative knockouts of its real, closest homologs to assess redundancies.
Referee #2:
In the manuscript entitled " The Arabidopsis homolog of human G3BP1 is a key regulator of stomatal and apoplastic immunity", the authors identified a homologue of the human G3BP1 in Arabidopsis from a phosphoproteomic analysis of flg22-treated Arabidopsis plants. Atg3bp1 mutants display constitutively increased salicylic-dependent immune responses, which leads to enhanced resistance to Pseudomonas syringae infection. While the identification of AtG3BP1 as a negative regulator of immunity is of interest, the current manuscript seems premature -especially when considering publication in a journal such as EMBO J.
Major comments: 1. Although G3BP1 was first identified as a flg22-responsive phosphoprotein, the authors make no attempt to test the functional relevance of phosphorylation on Ser-257, and to identify which kinase(s) is/are responsible for this phosphorylation.
2. Similarly, G3BP1 is a conserved RNA-binding. So, is RNA-binding capacity required for the reported function of G3BP1 in plant immunity? To which transcripts does G3BP1 bind during immunity? The authors discuss the published roles of mammalian G3BP1 and Arabidopsis G3BP1-like in stress granules. Thus, is G3BP1 SG-localised?
3. The sub-cellular localization of G3BP1 is poorly investigated in the study. This should be analysed upon expression of the protein under the control of its native promoter, and it should be tested whetehr the epitope-tagged G3BP1 protein can complement the g3bp1-1 mutant. Also, subcellular localization of G3BP1 should be studied in leaf tissues, as these are the parts of the plant that are used for all experiments.
4. There are no experimental details provided for the phosphoproteomics experiments, which makes it difficult to assess whether G3BP1 is truly a MAMP-responsive phosphoprotein.
Minor comments:
5. The authors describe a family G3BP1-like proteins in Arabidopsis containing 17 members. Please discuss what criteria were used to define this family. Several members of the 'family' are actually NBS-LRR proteins (e.g. ADR1 discussed in the text), which do not seem to contain the NTF2 or RNA-binding domains of G3BP1 and seem to share very little sequence homology. Maybe it would also be helpful to include a multiple alignment in the supplemental figures. In addition, HsG3BP1 should also be included in the phylogenetic tree.
6. On a related note, no information is provided on how the phylogenetic tree and multiple alignment in Sup Fig1 were produced.
7. In the abstract, the authors claim there is no growth or developmental defects. This conclusion is too strong from only showing images of 4-week-old plants. Other parameters (e.g. biomass) could easily be quantified to observe if there are more subtle phenotypes, which would be expected from a plant with some of the phenotypes shown by the mutant, such as constituviely reduced stomatal aperture.
8. There are several issues with Figure 2 . -In the materials and methods, the authors state that the seedlings are all 10-days-old. There is a clear age difference between panel I and II. -The ATG3BP1 promoter does not appear to be active in leaves from the panel I and II, which seems to be in contrast to what observed in panels iii and iv. The stomata do not appear to have stronger staining in III; is panel IV representative? -State which transgenic line was used. One has much higher expression and would be more likely to have overexpression artefacts. -A better resolution would be required for publication.
9. The authors should test the genetic interaction between ATG3BP1 and key components of the SA signalling pathway e.g. crossing with sid2 to determine if mutant phenotypes such as gene expression are abolished in an SA deficient background.
10. The authors should perform the stomatal assays following application of both exogenous coronatine and JA. The data suggests that there is a constitutive activation of SA signalling which cannot be suppressed by coronatine. Can this be overcome by application of higher concentrations of JA or coronatine?
11. The Atg3bp1 alleles display higher immune responses but less callose deposition is observed in these mutants which seems counter-intuitive. The authors should discuss this point. Also, it is not correct to state that "AtGB3BP1...may not be important for some aspects of the late apoplastic MTI responses, notably callose deposition" given that the the Atg3bp1 mutants had less callose deposits upon flg22 treatment. This actually demonstrates that AtGB3BP1 is important for this response.
12. In Figure 4 , how do the authors explain that the Atg3bp1-1 mutant show lower Pst DC300 titers at 3 hpi in panel D, while this is not the case on panel H; despite the fact that the legens indicate that the experimenta conditions were similar?
13. The authors should consider renaming the gene considering Krapp et al. (2017) named a homolog of this gene 'G3BP-like protein (AtG3BP)', which will lead to confusion.
Referee #3:
This manuscript describes that Arabidopsis G3BP1 (At5g48650) is a negative regulator of plant immunity against the bacterial pathogen Pseudomonas syringae. Mutants deficient in this gene showed constitutive immune responses (enhanced ROS and SA and constitutive closure of stomata), which likely explain resistance phenotypes of this mutant.
The family G3BP genes have "almost" never been characterized in terms of plant immunity, and therefore genetic evidence provided in this manuscript is interesting and novel. However, this manuscript does not provide any mechanistic insight into how G3BP1 regulates immunity or how G3BP1 is regulated during immunity. Thus, this manuscript remains descriptive and to this reviewer does not significantly contribute to the field of plant immunity at the level of this journal. Many negative regulators in plant immunity whose mutants show constitutive immune responses have been characterized. Such mutants including the ones in this study show heightened ROS and SA signaling. Therefore, without showing a mechanism, this study joins in already existing collections of mutant reports for negative regulators of plant immunity whose functions remain obscure.
Constitutive defense mutants often exhibit growth defects. In contrast, mutants in this study do not appear to show such developmental phenotypes (at least the authors claim but evidence is weak, though). Thus, this observation could potentially be interesting if the authors show why mutants deficient in this gene show normal growth phenotype. Since defense and growth tradeoff is well described and a problem in agriculture, such mechanistic insight would attract large audiences.
Besides general significance, there are several issues (please see below in detail) that the authors should consider to improve this manuscript. In particular, the phylogenetic tree (FigS1) seems not right.
In summary, this manuscript would be potentially interesting to a wide range of audiences but remains descriptive without a mechanistic insight. In addition, some conclusions are not justified by presented evidence and some descriptions are overstated. In addition, some experimental issues need to be solved.
(Major comments) 1. Regarding the phylogenetic tree of Arabidopsis G3BP family (FigS1). In the tree, the closest homolog (At5g47280) of the gene described in this study (At5g48650) is ADR1-L3, which belongs to NLR family like other ADR1 genes. G3BP and NLR family do not have similar structure or sequence, so this result appears to contain some error. I also double checked if At5g47280 and At5g48650 have similar sequences, but I failed to see a similarity. Related to this, in Discussion the authors discuss about At5g47280 (Page 16 "Interestingly, another closely related member of....including PR1"). I think that this paragraph has at least three errors. 1) At5g47280 does not seem to be related to G3BP. 2) At5g47280 is not ADR1 but is ADR1-L3. As far as I know, mutants of At5g47280 have not characterized in publication. 3) In the adr1 mutant paper (Grant et al 2003 MPMI), they characterized activation tagging lines of ADR1 (more or less overexpression of ADR1). Furthermore, this paragraph is inconsistent with the statement in Introduction "so far no role of G3BP has been reported in plants". Related to this point, how did the authors identify Arabidopsis G3BP genes? This needs explanation. 5. Page 2 "insensitivity to bacterial coronatine...reopening" g3bp1 mutants show constitutive closed stomatal phenotypes regardless of treatments (i.e. Fig6E). Therefore, insensitivity to bacterial coronatine mediated stomatal "reopening" is misleading. To this reviewer, stomata aperture of g3bp mutants does not change except after ABA treatment.
6. Regarding phosphorylation of G3BP1. Is phosphorylation important for function in immunity? It is rather surprising that the authors did not test by complementing mutant lines with phosphormimic and phosphor-deficient versions of G3BP1, since phosphorylation of G3BP1 in flg22 response was the start of this study. These experiments will strengthen the quality of this study. -Page 6. Since both g3bp1 mutants have an insertion at exons, to this reviewer, these mutants are not "transcriptionally knock-down mutants". Likely knockout mutants. -As the authors discuss (Krapp et al 2017), this is not the first study showing implication of G3BP family proteins in plant immunity. Thus, Page3 "but so far no role of G3BP has been reported in plants" should be toned down. -Page12 "Among these genes...SA-related genes" needs data. -Transcriptome data. Since g3bp1 mutants show constitutive stomatal closure, differential transcriptome patterns in WT and mutants could be simply caused by different bacterial loads. To understand roles of G3BP1 in plant immunity, bacterial infiltration or MAMP treatments would have been much better. The authors can investigate by qRTPCR for some gene expression in WT and mutants in response to bacterial infiltration or MAMPs.
1st Revision -authors' response 6 March 2018
All the 3 reviewers pointed out the error in the inclusion of ADR1 (At5g47280) as an Arabidopsis G3BP homolog, on careful re-analysis of the data, we found that there was an error in the association of the Uniprot accession codes to the Arabidopsis AGI codes in the database, as the gene model considered is incorrect. To rule out the possible mistakes with the other not so obvious candidates, we looked up all the Arabidopsis G3BP homologs that we had reported in the manuscript and noticed that Uniprot had given different AGI codes to splice variants of the same gene. To rectify this error, we revised the number of Arabidopsis G3BPs genes to be only 8 in total after cross verification with the Arabidopsis TAIR database. The revised version of the manuscript submitted now incorporates all the corrections in the text as well as in the respective figures and expression profiles.
Below are the specific changes brought about in the manuscript.
Page 3, Line 21 -22 : We have changed the sentence from "Here, we identify the Arabidopsis G3BP1 homolog that belongs to a family of 16 proteins and functions in plant immunity." to "Here, we identify the Arabidopsis G3BP1 homolog that belongs to a family of 8 proteins and functions in plant immunity."
Page 6, Line 1 -3 : We have changed the sentence from "The Arabidopsis genome codes for 16 proteins, which satisfy these criteria. The 16 Arabidopsis G3BPs are named AtG3BP1 to AtG3BP16 as indicated in ( Figure S1A )." to "The Arabidopsis genome codes for 8 proteins, which satisfy these criteria. The 8 Arabidopsis G3BPs are named AtG3BP1 to AtG3BP8 as indicated in ( Figure S1A )." Figure S1A has been updated to show only 8 G3BP proteins now. Figure 1A now shows the tree with only 8 Arabidopsis G3BPs and the Human G3BP1.
Page 13, Line 20 -22 : We have changed the sentence from "AtG3BP1 is a member of a family of 16 proteins in Arabidopsis that are orthologs to the human G3BP gene family." to "AtG3BP1 is a member of a family of 8 proteins in Arabidopsis that are orthologs to the human G3BP gene family." Figure S4 has now been updated with the expression for the 8 G3BPs in place of the 16 G3BPs.
1st Editorial Decision 4 April 2018
Thank you for submitting your manuscript entitled "The Arabidopsis homolog of human G3BP1 is a key regulator of stomatal and apoplastic immunity" to Life Science Alliance. Your manuscript was previously reviewed at another journal, and the reviewer reports were confidentially transferred to Life Science Alliance with your permission. I had asked you prior to your submission to provide a point-by-point response and to address the following concerns of the previous round of review:
-Referee #1: specific comments -Referee #2: points 3 and 4 and minor points 5-8.
-Referee #3: points 1 and 2, and the concerns in (other comments)
Your revised version has been seen by one of the original reviewers again, and I am afraid that this reviewer thinks that the data provided are not sufficiently addressing the concerns I asked you to address. Specifically, the sub-cellular localization of AtG3BP1 (referee #2, point 3) is not satisfactorily documented, and the anti-GFP blot for the overexpression line should be provided in full (referee #1, specific comment). Furthermore, the reviewer notes that the text could benefit from another revision.
I would thus like to ask you to provide a final revision, addressing these points. I should stress that we usually only allow a single round of revision.
We hope that the comments below will prove constructive as your work progresses. We would be happy to discuss them further once you've had a chance to consider the points raised in this letter.
Thank you for this interesting contribution to Life Science Alliance. We are looking forward to receiving your revised manuscript.
2nd Revision -authors' response 17 May 2018
Reviewer #1 (Comments to the Authors (Required)):
This new manuscript submitted is improved, mostly because it is now more focused on the genetic role of AtG3BP1 as a negative regulator of immunity against Pseudomonas syringae.
I however still feel that the sub-cellular localization of AtG3BP1 is poorly documented, as the Figure 2C would need to be at higher maginification to allow any meaningful conclusion. Also, while I appreciate the efforts done to provide the requested anti-GFP western blot for the line OE3, this analysis is not really useful without showing the full blot, as it is important to check whether the protein is cleaved given that free GFP will display the reported nucleo-cytoplasmic localization.
We have now thoroughly investigated the sub-cellular localization of AtG3BP1 in the stable Arabidopsis overexpressor lines as well as transiently in N. benthamiana leaf epidermal cells. We have modified Figure 2 with better images with higher resolution to clearly make a conclusion about the localization of AtG3BP1. In addition, we also carried out the western blot analysis and now we show the full blot to confirm that the GFP tag is not cleaved from the protein.
In the Introduction and Discussion, a number of references used to refer to MTI outputs are not always the original ones, or there is a lack of consistency in the citation of primary research articles versus review articles. My suggestion would be therefore to cite simply a recent comprehensive review on the topic, such as Yu et al., Annu. Rev Phytopathol. 2017 (doi: 10.1146 . Also, when referring to specific proteins (e.g. MPK3, MPK4, etc...), specify that these correspond to proteins known in Arabidopsis thaliana. (Torres, Jones et al., 2006) , an increase in intracellular calcium concentration (Liese & Romeis, 2013) , and activation of four known Arabidopsis mitogen-activated protein kinases namely MPK3, MPK4, MPK6 and MPK11 (Frei dit Frey, Garcia et al., 2014 , Ranf, Eschen-Lippold et al., 2011 , Zipfel, Kunze et al., 2006 .
In the Introduction (p. 5), when summarizing the litterature on auto-immune mutants and the phenotypes conferred by SA imbalance, it is not necessarily correct to simply refer to "pathogens", as the phenotypes are often opposite when considering hemi-/biotrophs versus necrotophs. Figure 3B , Figure 4D , Figure 4G and Figure 4H .
Discussion, p. 14: it is odd to write "...confirmed the role of AtG3BP1 in plant innate immunity", as it suggests that this role had already been reported before.
As per the suggestion by the reviewer, we have now changed the sentence to read as follows -"The enhanced disease resistance to Pst observed in two independent Atg3bp1 loss of function mutant lines indicates a role for AtG3BP1 in plant innate immunity."
Given that the authors report here the family to which AtG3BP1 belongs to, it would be good, for clarity, to refer to the previously studied At5g43960 as AtG3BP7 when first referred to in the text.
We have now made this modification in the discussion part of the manuscript as we propose the nomenclature for these genes in the first part of the results section. We decided to call it in the introduction where we first refer to this gene.
In the Discussion, it would be great if the authors could speculate on why altered AtG3BP1 expression affects ROS production, which is a very early MTI responses occuring within a few minutes. Also, given that AtG3BP1 has homology to a RNA-binding protein, it would be good to discuss at least how this protein could regulate immunity mechanistically. ' (Kedersha et al., 2013) . A good example for this as signaling hub is the shown by HsG3BP1 which functions in regulating doublestranded RNA-dependent protein kinase activation (Reineke et al., 2015) . (Kadota et al., 2014 , Melotto et al., 2006 , Yu et al., 2017 Thank you for submitting your revised manuscript entitled "The Arabidopsis homolog of human G3BP1 is a key regulator of stomatal and apoplastic immunity".
I appreciate the introduced changes, and I am happy to accept your manuscript in principle for publication in Life Science Alliance.
Thank you for this interesting contribution, we look forward to publishing your paper in Life Science Alliance.
